By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Investors are suing China Medical Technologies alleging the firm engaged in actions that artificially inflated its stock in violation of US securities law.

The Beijing-based in vitro diagnostics firm has been hit with at least three class action lawsuits in the past two months, including two filed in the past week, in which plaintiffs accuse the company of making false and/or misleading statements, and withholding material and adverse information.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Liquid biopsies and DNA tests may be able to tell physicians whether a cancer patient is relapsing, the New York Times reports.

In PLOS this week: GWAS links gene to noise-induced hearing loss in mice, population genetics of malaria parasites, and more.

Nautilus' Alexandra Ossola examines how Tay-Sachs disease jump-started the genetic disease testing field.

FASEB says guidelines proposed by the NIH to bolster research reproducibility are premature and don't take the full range of scientific studies into consideration.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.